Publications
> Manuals > Practitioner's
Manual - Section I
SECTION I - INTRODUCTION
This practitioner’s manual is intended to summarize and explain the basic
requirements for prescribing, administering, and dispensing controlled
substances under the Controlled Substances Act (CSA), 21 USC 801-890, and the
DEA regulations, Title 21, Code of Federal Regulations (CFR), Parts
1300 to 1316. Pertinent citations to the law and regulations are included in
this manual.
Printed copies of the CFR and the complete regulations implementing the CSA
may be obtained from:
Superintendent of Documents
U.S. Government Printing Office
Washington, D.C. 20402
Both the CFR and the Federal Register (which includes proposed and
final regulations implementing the CSA) are available on the Internet through
the U.S. Government Printing Office (GPO) website. This website, which
provides information by section, citation and keywords, can be accessed at:
www.gpoaccess.gov/cfr/index.html
Unofficial copies of pertinent CFR citations may be found at:
www.DEAdiversion.usdoj.gov
This practitioner’s manual may also be found on the Internet at DEA’s
Web Site (under "publications"):
www.DEAdiversion.usdoj.gov
Should any pertinent provisions of the law or regulations be modified in
the future, DEA will issue a revised electronic version of this document,
which will be published on the DEA Diversion Website.
If you encounter errors in this document, please notify:
Editor, DEA Practitioner’s Manual
c/o DEA, Office of Diversion Control
Liaison and Policy Section
Washington, D.C. 20537
Inquiries regarding topics within this document may be addressed to your
local DEA field office (listed in Appendix
E) or the address above.
This Document is Authorized for Public Dissemination
All material in this publication is in the public domain and may be
reproduced without the express permission of the Drug Enforcement
Administration.
Message from the Administrator
The Drug Enforcement Administration is pleased to provide this updated
edition of the 1990 Practitioner’s Manual to assist you in understanding
your responsibilities under the Controlled Substances Act (CSA) and its
implementing regulations. This manual will help answer questions that you may
encounter in your practice and provide guidance in complying with federal
requirements.
DEA remains committed to the 2001 Balanced Policy of promoting pain relief
and preventing abuse of pain medications. In
enforcing the CSA, it is DEA’s responsibility to ensure drugs are not
diverted for illicit purposes. Unfortunately, this country is now experiencing
an alarming prescription drug abuse problem:
- Today, more than 6 million Americans are abusing prescription drugs—that
is more than the number of Americans abusing cocaine, heroin,
hallucinogens, and inhalants, combined.
- Researchers from the Centers for Disease Control and Prevention report
that opioid prescription painkillers now cause more drug overdose deaths
than cocaine and heroin combined.
- Today more new drug users have begun abusing pain relievers (2.4
million) than marijuana (2.1 million) or cocaine (1.0 million).
It is more important now than ever to be vigilant in preventing the
diversion and abuse of controlled substances. This manual will help you do
that by listing some safeguards you can take to prevent such diversion. It
also explains registration, recordkeeping, and valid prescription
requirements.
As a practitioner, your role in the proper prescribing, administering, and
dispensing of controlled substances is critical to patients’ health and to
safeguarding society against the diversion of controlled substances. DEA is
committed to working jointly with the medical community to ensure that those
in need are cared for and that legitimate controlled substances are not being
diverted for illegal use.
Karen P. Tandy
Administrator
September 2006
Preface
The Drug Enforcement Administration (DEA) was established in 1973 to serve
as the primary federal agency responsible for the enforcement of the
Controlled Substances Act (CSA). The CSA sets forth the federal law regarding
both illicit and licit (pharmaceutical) controlled substances. With respect to
pharmaceutical controlled substances, DEA’s statutory responsibility is
twofold: to prevent diversion and abuse of these drugs while ensuring an
adequate and uninterrupted supply is available to meet the country’s
legitimate medical, scientific, and research needs. In carrying out this
mission, DEA works in close cooperation with state and local authorities and
other federal agencies.
Under the framework of the CSA, the DEA is responsible for ensuring that
all controlled substance transactions take place within the "closed
system" of distribution established by Congress. Under this "closed
system," all legitimate handlers of controlled substances –
manufacturers, distributors, physicians, pharmacies, and researchers – must
be registered with DEA and maintain strict accounting for all distributions.
To carry out DEA’s mission effectively, this 2006 Practitioner’s Manual
seeks to aid DEA registrants in complying with the CSA and its implementing
regulations. The DEA understands that it can best serve the public interest by
working with practitioners to prevent diversion of legal pharmaceutical
controlled substances into the illicit market.
The federal controlled substances laws are designed to work in tandem with
state controlled substance laws. Toward this same goal, DEA works in close
cooperation with state professional licensing boards and state and local law
enforcement officials to ensure that pharmaceutical controlled substances are
prescribed, administered, and dispensed for legitimate medical purposes in
accordance with federal and state laws. Within this cooperative framework, the
majority of investigations into possible violations of the controlled
substances laws are carried out by state authorities. However, DEA also
conducts investigations into possible violations of federal law as
circumstances warrant.
In the event a state board revokes the license of a practitioner, the DEA
will take action and request a voluntary surrender of the practitioner’s DEA
registration. If the practitioner refuses to voluntarily surrender the
registration, the DEA will pursue administrative action to revoke the DEA
registration. The DEA may also pursue judicial action if there is sufficient
evidence of illegal distribution or significant recordkeeping violations. All
such actions are intended to deny the practitioner the means to continue to
divert or abuse controlled substances as well as to protect the health and
safety of the public and the practitioner.
The DEA is authorized under federal law to pursue legal action in order to
prevent the diversion of controlled substances and protect the public safety.
A lack of compliance may result in a need for corrective action, such as
administrative action (that is, Letter of Admonition, an informal hearing or
"order to show cause"), or in extreme cases, civil, or criminal
action.
Table
of Contents | Section II
Download
Practitioner's Manual PDF
u:012908
|